Your browser doesn't support javascript.
loading
A glycolytic metabolite bypasses "two-hit" tumor suppression by BRCA2.
Kong, Li Ren; Gupta, Komal; Wu, Andy Jialun; Perera, David; Ivanyi-Nagy, Roland; Ahmed, Syed Moiz; Tan, Tuan Zea; Tan, Shawn Lu-Wen; Fuddin, Alessandra; Sundaramoorthy, Elayanambi; Goh, Grace Shiqing; Wong, Regina Tong Xin; Costa, Ana S H; Oddy, Callum; Wong, Hannan; Patro, C Pawan K; Kho, Yun Suen; Huang, Xiao Zi; Choo, Joan; Shehata, Mona; Lee, Soo Chin; Goh, Boon Cher; Frezza, Christian; Pitt, Jason J; Venkitaraman, Ashok R.
Affiliation
  • Kong LR; Cancer Science Institute of Singapore, Singapore 117599, Singapore; NUS Centre for Cancer Research (N2CR), National University of Singapore, Singapore 117599, Singapore; MRC Cancer Unit, University of Cambridge, Cambridge CB2 0XZ, UK; Department of Pharmacology, National University of Singapore, Sin
  • Gupta K; Cancer Science Institute of Singapore, Singapore 117599, Singapore; MRC Cancer Unit, University of Cambridge, Cambridge CB2 0XZ, UK.
  • Wu AJ; Cancer Science Institute of Singapore, Singapore 117599, Singapore.
  • Perera D; MRC Cancer Unit, University of Cambridge, Cambridge CB2 0XZ, UK.
  • Ivanyi-Nagy R; Cancer Science Institute of Singapore, Singapore 117599, Singapore.
  • Ahmed SM; Cancer Science Institute of Singapore, Singapore 117599, Singapore.
  • Tan TZ; Cancer Science Institute of Singapore, Singapore 117599, Singapore.
  • Tan SL; MRC Cancer Unit, University of Cambridge, Cambridge CB2 0XZ, UK; Institute of Molecular and Cell Biology (IMCB), A(∗)STAR, Singapore 138673, Singapore.
  • Fuddin A; Cancer Science Institute of Singapore, Singapore 117599, Singapore.
  • Sundaramoorthy E; Cancer Science Institute of Singapore, Singapore 117599, Singapore.
  • Goh GS; Cancer Science Institute of Singapore, Singapore 117599, Singapore.
  • Wong RTX; Cancer Science Institute of Singapore, Singapore 117599, Singapore.
  • Costa ASH; MRC Cancer Unit, University of Cambridge, Cambridge CB2 0XZ, UK.
  • Oddy C; Department of Oncology, University of Cambridge, Cambridge CB2 0XZ, UK.
  • Wong H; Cancer Science Institute of Singapore, Singapore 117599, Singapore.
  • Patro CPK; Cancer Science Institute of Singapore, Singapore 117599, Singapore.
  • Kho YS; Cancer Science Institute of Singapore, Singapore 117599, Singapore; NUS Centre for Cancer Research (N2CR), National University of Singapore, Singapore 117599, Singapore.
  • Huang XZ; Cancer Science Institute of Singapore, Singapore 117599, Singapore; NUS Centre for Cancer Research (N2CR), National University of Singapore, Singapore 117599, Singapore.
  • Choo J; Department of Medicine, National University of Singapore, Singapore 119228, Singapore.
  • Shehata M; MRC Cancer Unit, University of Cambridge, Cambridge CB2 0XZ, UK; Department of Oncology, University of Cambridge, Cambridge CB2 0XZ, UK.
  • Lee SC; Cancer Science Institute of Singapore, Singapore 117599, Singapore; NUS Centre for Cancer Research (N2CR), National University of Singapore, Singapore 117599, Singapore; Department of Medicine, National University of Singapore, Singapore 119228, Singapore.
  • Goh BC; Cancer Science Institute of Singapore, Singapore 117599, Singapore; NUS Centre for Cancer Research (N2CR), National University of Singapore, Singapore 117599, Singapore; Department of Medicine, National University of Singapore, Singapore 119228, Singapore.
  • Frezza C; MRC Cancer Unit, University of Cambridge, Cambridge CB2 0XZ, UK; University of Cologne, 50923 Köln, Germany.
  • Pitt JJ; Cancer Science Institute of Singapore, Singapore 117599, Singapore; NUS Centre for Cancer Research (N2CR), National University of Singapore, Singapore 117599, Singapore; Genome Institute of Singapore, A(∗)STAR, Singapore 138673, Singapore.
  • Venkitaraman AR; Cancer Science Institute of Singapore, Singapore 117599, Singapore; NUS Centre for Cancer Research (N2CR), National University of Singapore, Singapore 117599, Singapore; MRC Cancer Unit, University of Cambridge, Cambridge CB2 0XZ, UK; Institute of Molecular and Cell Biology (IMCB), A(∗)STAR, S
Cell ; 187(9): 2269-2287.e16, 2024 Apr 25.
Article in En | MEDLINE | ID: mdl-38608703
ABSTRACT
Knudson's "two-hit" paradigm posits that carcinogenesis requires inactivation of both copies of an autosomal tumor suppressor gene. Here, we report that the glycolytic metabolite methylglyoxal (MGO) transiently bypasses Knudson's paradigm by inactivating the breast cancer suppressor protein BRCA2 to elicit a cancer-associated, mutational single-base substitution (SBS) signature in nonmalignant mammary cells or patient-derived organoids. Germline monoallelic BRCA2 mutations predispose to these changes. An analogous SBS signature, again without biallelic BRCA2 inactivation, accompanies MGO accumulation and DNA damage in Kras-driven, Brca2-mutant murine pancreatic cancers and human breast cancers. MGO triggers BRCA2 proteolysis, temporarily disabling BRCA2's tumor suppressive functions in DNA repair and replication, causing functional haploinsufficiency. Intermittent MGO exposure incites episodic SBS mutations without permanent BRCA2 inactivation. Thus, a metabolic mechanism wherein MGO-induced BRCA2 haploinsufficiency transiently bypasses Knudson's two-hit requirement could link glycolysis activation by oncogenes, metabolic disorders, or dietary challenges to mutational signatures implicated in cancer evolution.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyruvaldehyde / Breast Neoplasms / BRCA2 Protein / Glycolysis Limits: Animals / Female / Humans Language: En Journal: Cell Year: 2024 Document type: Article Country of publication: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyruvaldehyde / Breast Neoplasms / BRCA2 Protein / Glycolysis Limits: Animals / Female / Humans Language: En Journal: Cell Year: 2024 Document type: Article Country of publication: Estados Unidos